Labiotech.eu

Can bispecific ADCs be the future of targeted cancer therapy? 🎯 Antibody-drug conjugates (ADCs) have transformed oncology, but balancing effectiveness with off-target toxicity remains a challenge. Enter bispecific ADCs – a promising next-gen approach that aims to improve tumor targeting and address tumor heterogeneity. With multiple early-stage trials underway and significant dealmaking, this space is heating up. 🔥 This week, we dive into the potential of bispecific ADCs with Radek Spisek, CEO of SOTIO Biotech. 🎤 Listen now!  🎧 https://lnkd.in/dSPa8FzW #BeyondBiotechPodcast #BispecificADCs #cancertherapy #targetedtherapies #oncologyinnovation #ADCtechnology #cancerresearch

Thinking about starting a biotech company?💡 Building a biotech startup is a unique challenge that requires navigating scientific validation, regulatory hurdles, and securing funding. Founders must choose the right focus, attract talent, and understand the importance of intellectual property. But the potential rewards are immense for those who can persevere through the complexities.✨ Labiotech reached out to several biotech founders to give practical advice to aspiring entrepreneurs. 🤝 Discover what they learned from their experience! ⬇️ https://lnkd.in/dCuKmuhB #biotechstartup #entrepreneurship #startupchallenges #scientificinnovation #biotechjourney #startupadvice #biotechsuccess Alexander Shneider | CureLab Oncology | Xavier Duportet | Eligo Bioscience | Mati Gill | AION Labs | Jennifer Good | Trevi Therapeutics, Inc. | Paul Jaminet | Angiex Inc.

💰 Biotech's Top Investments This Week! 🚀 🇺🇲 City Therapeutics | $135 million series A | RNAi-based medicines | IND-enabling in undisclosed indication 🇺🇲 Triveni Bio | $115 million series B | antibody therapies | preclinical in immunological & inflammatory (I&I) disorders 🇬🇧 Purespring Therapeutics | $105 million series B | gene therapies | IND-enabling in IgA Nephropathy 🇺🇲 Judo Bio | $100 million seed and series A | oligonucleotide therapies | preclinical in kidney disease 🇬🇧 Resolution Therapeutics | $85 million series B | macrophage therapies | phase 1/2 in end-stage liver disease 🇬🇧 Enara Bio | $42.6 million series B | TCR-based immunotherapies | preclinical in solid tumors 🇺🇲 Integrated Biosciences, Inc. | $17.2 million seed | age-related diseases drug discovery 🇨🇭 Somagenetix | $11.7 million series A | gene therapies | preclinical in phagocyte disorders Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding

Biotech IPOs are back! 🚀What does it mean for the industry? 🤔 The second wave of biotech IPOs this year has raised over $1.1 billion in Q3, signaling a potential market rebound. Driven by lower interest rates, this surge includes high-profile debuts like Bicara Therapeutics and Zenas BioPharma. While challenges remain, this uptick hints at renewed investor confidence and opportunities for biotech startups. 🤝💸 Explore the factors behind this IPO boost and what it could mean for the future of biotech funding. 🔎 Read more here ⬇️ https://lnkd.in/dD5dJe3v #biotechIPOs #biotechinvesting #biopharmanews #startupfunding #biotechstartups #biotechinnovation MBX Biosciences, Inc. | Kairos Pharma Ltd. (NYSE: KAPA) | BioAge Labs | Tim Opler | Stifel Institutional | Clarivate | Martin Turner | BioIndustry Association (BIA) | David Buller | KELES

Have you ever heard of a biotech unicorn? 🦄💡 Although a mythological creature might be what first springs to mind, a unicorn in the business world actually refers to a privately owned company valued at more than $1 billion. The reason they are called “unicorns” is because it is traditionally very rare for a company to achieve this valuation. 📈💰 In the biotech world, there are only a select few companies with unicorn status that are working on therapeutics. 🏆 Read our latest article, as we take a closer look at 12 biotech unicorns! 👇️ https://lnkd.in/eMQ6vp7k #biotechunicorns #biotechinnovation #biopharmagiants #startupsuccess #biotechworld #techvaluation Abogen, Inc. | Eikon Therapeutics | insitro | Xaira Therapeutics | Cambrian Bio | Tessera Therapeutics | Orna Therapeutics | Generate:Biomedicines | Kallyope | IntraBio Inc | Mammoth Biosciences | Owkin

Greetings from CPHI Milan! 👋 Freya Damrell is thrilled to be here and connect with professionals from the pharma, biotech, CDMO, CRO, and related industries looking to take their businesses to the next level. She’s eager to discuss how Labiotech can help enhance visibility and drive leads for your organization. 🚀 If you’re attending the event, let’s chat! 💬 Feel free to reach out to Freya Damrell via direct message. #CPHI2024 #CPHI #CPHIMilan #CPHI2024 #CPHIMilan2024 #PharmaEvent #CPHICelebration #Biopharma #Bioproduction CPHI

Did you know that chronic obstructive pulmonary disease (COPD) is actually the third leading cause of death worldwide? 🫁 After more than a decade with no new therapeutic advancements, interest in COPD seems to have grown in the last year, which can be evidenced by the recent regulatory approvals of Verona Pharma’s Ohtuvayre and Regeneron and Sanofi’s blockbuster drug Dupixent. 💊 But what about a cure for COPD? Well, transplanting patients’ own lung cells could hold promise here. 🌱 Read our latest article to find out all about these recent advancements in COPD research! 👇 https://lnkd.in/d9X3xWx6 #COPD #chronicdisease #lunghealth #biotechinnovation #celltherapy #lungtransplantation #pharmanews #medicalresearch European Respiratory Society | GSK | Amgen | AstraZeneca | Global Initiative for Chronic Obstructive Lung Disease | British Thoracic Society (BTS) | COPD Foundation | Global Initiative for Asthma | European Lung Foundation | American Lung Association | British Lung Foundation | Canadian Lung Association | European Lung Foundation | The Pulmonary Education and Research Foundation (PERF)

September 2024: Top biotech deals of the month.

The future of 3D organoids: Can automation and AI unlock their full potential? 🚀 In the race to advance 3D cell models, automation and artificial intelligence are transforming how organoids are developed and analyzed. These technologies are improving reproducibility and throughput while helping researchers get more meaningful insights. 💡 Discover how AI and automation are shaping the next generation of 3D organoid research in our latest Sartorius-sponsored report. 🗒️ Check it out here ⬇️ https://lnkd.in/d-sqffs9 #3Dorganoids #biomedicalresearch #drugdiscovery #healthcareinnovation #organoidtechnology #biotechrevolution #biotechtrends

🔬💡Can advanced mass spectrometry save your biopharmaceutical batch from failure? KBI Biopharma recently faced a high-stakes issue: an unexpected pink discoloration in a GMP batch. 🧪 Thanks to cutting-edge mass spectrometry, the root cause was identified, and the batch was saved from a costly loss. 💰 This showcases the importance of having expert analytical capabilities. Learn how KBI Biopharma's quick action and advanced technology turned a challenge into success. ✅ Check out the full article below. ⬇️ https://lnkd.in/eT9EBtXY   #biotechinnovation #biomanufacturing #cellculture #biotechnews #healthcareinnovation #biotech